Tirzepatide is a gastric inhibitory polypeptide (GIP) analog and a GLP-1 receptor agonist.^[10] It is used as an antidiabetic medication to treat type 2 diabetes^{[9][12][13][14]} and for weight loss.^[10][15] Tirzepatide is administered via subcutaneous injections (under the skin).^[9][12] It is sold in several countries under the brand name Mounjaro for diabetes treatment.^[9] In the United States it is sold under the brand name Zepbound for weight loss and treatment of obstructive sleep apnea.^[10][16]

The most frequent side-effects of tirzepatide include nausea, vomiting, diarrhea, decreased appetite, constipation, upper abdominal discomfort, and abdominal pain.^[9][12][17] Developed by Eli Lilly and Company, tirzepatide was approved for treatment of diabetes in the US in May 2022,^[9][12] in the European Union in September 2022,^[11] in Canada in November 2022,^[18] and in Australia in December 2022.^[2] The US Food and Drug Administration (FDA) considers it a first-in-class medication.^[19][20] The FDA approved it for weight loss in November 2023.^[15][21] Also in November 2023, the UK Medicines and Healthcare products Regulatory Agency revised the indication for tirzepatide (as Mounjaro) to include the treatment for weight management and weight loss.^[8][22] In December 2024, the FDA revised the indication for tirzepatide (as Zepbound) to include the treatment of moderate to severe obstructive sleep apnea.^[10][16] In 2023, tirzepatide was the 110th most commonly prescribed medication in the United States, with more than 6 million prescriptions.